International Summit on Human Gene Editing

International Summit on Human Gene Editing
Name	International Summit on Human Gene Editing
Date	2015, 2018, 2023
Location	United States, United Kingdom, China
Participants	Scientists, ethicists, policymakers
Organized	National Academy of Sciences, National Academy of Medicine, Royal Society, Chinese Academy of Sciences

Contents

International Summit on Human Gene Editing. The International Summit on Human Gene Editing convened leading figures from National Academy of Sciences, National Academy of Medicine, Royal Society, Chinese Academy of Sciences and other institutions to address developments in CRISPR-Cas9, zinc finger nuclease, TALEN technologies and their application to germline modification, somatic cell therapy, embryo research and related fields. The Summit aimed to bridge perspectives from stakeholders at Harvard University, Massachusetts Institute of Technology, Stanford University, University of Oxford, Peking University and international bodies such as the World Health Organization and the United Nations Educational, Scientific and Cultural Organization. Participants included representatives from the Wellcome Trust, Bill & Melinda Gates Foundation, European Commission, U.S. Food and Drug Administration, Chinese Academy of Medical Sciences and leading research centers like the Broad Institute and the Salk Institute.

Background and purpose

The Summit emerged amid rapid advances exemplified by work from teams at Broad Institute of MIT and Harvard and UC Berkeley and controversies such as the disputed embryo editing reports associated with He Jiankui and debates in venues like the Biophysical Society and American Association for the Advancement of Science. Organizers sought convergence among actors from National Institutes of Health, European Molecular Biology Laboratory, Howard Hughes Medical Institute, Wellcome Trust, World Health Organization, and the United Nations to craft guidance responsive to innovations from laboratories including Cold Spring Harbor Laboratory and Max Planck Society. The purpose was to evaluate scientific readiness for clinical use, assess risks observed in studies from Yale University, Johns Hopkins University, Karolinska Institute and to consider norms reflected in instruments like the Universal Declaration on Bioethics and Human Rights.

Scientific sessions surveyed gene-editing platforms such as CRISPR-Cas9, CRISPR-Cpf1, zinc finger nuclease, TALEN and delivery systems studied at Massachusetts General Hospital, Mayo Clinic, UCSF Medical Center and Cleveland Clinic. Presentations reviewed preclinical models from Salk Institute, Max Planck Institute, Riken, clinical trial frameworks at MD Anderson Cancer Center and translational pipelines influenced by programs at Broad Institute and Illumina. Technical issues included off-target effects documented by researchers at MIT, mosaicism reported in studies at Peking University Third Hospital, immune responses characterized by teams at National Institutes of Health and challenges in germline modification highlighted by work at Sun Yat-sen University and Shanghai Jiao Tong University.

Ethics panels drew on analyses from the Nuffield Council on Bioethics, Hastings Center, Kennedy Institute of Ethics, UNESCO and precedent from the Nuremberg Code and the Declaration of Helsinki. Discussions addressed consent frameworks used in trials at Johns Hopkins University, equitable access concerns raised by the Bill & Melinda Gates Foundation and regulatory harmonization debated between the European Commission, U.S. Food and Drug Administration and China Food and Drug Administration. Social implications considered inequalities noted in reports from World Health Organization, intellectual property issues involving Broad Institute and University of California, and cultural responses reflected in media from The Lancet, Nature (journal), Science (journal) and commentary in outlets like The New York Times and The Guardian.

Summit statements recommended moratoria or translational thresholds for clinical germline application echoed in documents from the National Academy of Sciences, National Academy of Medicine, Royal Society and Chinese Academy of Sciences. Recommendations urged establishment of registries similar to initiatives at the World Health Organization and collaborative governance models drawing on precedents from the International Committee of the Red Cross and Global Alliance for Genomics and Health. The Summit called for funding for safety research supported by entities like the Wellcome Trust, Howard Hughes Medical Institute and European Research Council, and for policy dialogues with regulators including the U.S. Food and Drug Administration and European Medicines Agency.

Responses included policy statements and working groups at World Health Organization, national reviews in bodies such as the United Kingdom Department of Health and Social Care, U.S. National Institutes of Health, China National Health Commission and legislative scrutiny in assemblies like the United States Congress and European Parliament. Research trajectories shifted with increased investment at centers such as Broad Institute, Salk Institute, Wellcome Sanger Institute and startups backed by Andreessen Horowitz and other investors, while academic discourse continued in Nature (journal), Science (journal), Cell (journal) and conferences including the American Society of Human Genetics and European Society of Human Genetics.

Category:Bioethics Category:Genetic engineering conferences